S1PR1 and glioblastoma: The impacts of ACT-209905 on the growth and migratory properties of human (LN18, U87MG and primary GBM cells) and mouse (GL261) GBM cells, as well as the potential synergistic effects in combination with temozolomide and other S1PR1/2 antagonists, were determined.